Peptide induces CD4(+)CD25+ and IL-10+ T cells and protection in airway allergy models. (Q47812455)

5 February 2018

title

Peptide induces CD4(+)CD25+ and IL-10+ T cells and protection in airway allergy models. (English)

1 reference

5 February 2018

author name string

Cindy L Zuleger

1

1 reference

5 February 2018

Xiaoyan Gao

2

1 reference

5 February 2018

Melissa S Burger

3

1 reference

5 February 2018

Qili Chu

4

1 reference

5 February 2018

Lendon G Payne

5

1 reference

5 February 2018

Dexiang Chen

6

1 reference

5 February 2018

language of work or name

English

0 references

publication date

1 May 2005

1 reference

5 February 2018

published in

Vaccine

1 reference

5 February 2018

volume

23

1 reference

5 February 2018

issue

24

1 reference

5 February 2018

page(s)

3181-3186

1 reference

5 February 2018

Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.012

Inhibition of T cell and antibody responses to house dust mite allergen by inhalation of the dominant T cell epitope in naive and sensitized mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.012

Regulation of house dust mite responses by intranasally administered peptide: transient activation of CD4+ T cells precedes the development of tolerance in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.012

Inhibition of mucosal and systemic T(h)2-type immune responses by intranasal peptides containing a dominant T cell epitope of the allergen Der p 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.012

Suppression of allergen reactive Th2 mediated responses and pulmonary eosinophilia by intranasal administration of an immunodominant peptide is linked to IL-10 production.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.012

Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.012

Allergen-derived T cell peptide-induced late asthmatic reactions precede the induction of antigen-specific hyporesponsiveness in atopic allergic asthmatic subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.012

Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.012

CD25+ CD4+ T cells regulate the expansion of peripheral CD4 T cells through the production of IL-10

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.012

Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.012

Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.012

An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.012

A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.012

Role of interleukin 10 in specific immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.012

A Comparative Study between T Regulatory Type 1 and CD4+CD25+ T Cells in the Control of Inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.012

10.1016/J.VACCINE.2004.12.012

7 January 2021

Identifiers

DOI

1 reference

5 February 2018

PubMed ID

15837218

1 reference

5 February 2018